OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations

• Operating expenses fell in Q1 after Omeros sold its experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.
• Omeros is now awaiting a European Medicines Agency decision on the Yartemlea marketing authorization application.

Omeros Corporation (OMER) shares rose more than 4% in after-hours trading on Wednesday after the company reported its first quarter of commercial revenue from the U.S. launch of YARTEMLEA for transplant-associated thrombotic microangiopathy (TA-TMA).

Omeros posted first-quarter net product sales of $9.9 million, compared with zero in the year-ago period when the drug was not yet approved or launched, and above an estimated $4.11 million. Adjusted net loss narrowed to $0.24 per share, compared to a loss of $0.58 in the corresponding quarter of last year, and below a loss of $0.29 expected by Wall Street analysts.

The company ended the quarter with $135.3 million in cash, cash equivalents, and short-term investments. Operating expenses fell sharply to $27.3 million from $35.0 million a year earlier, driven mainly by lower research and development spending after the earlier sale of the firm’s experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.

“The launch of YARTEMLEA has changed the trajectory of Omeros, both operationally and financially. We are seeing strong early adoption across transplant centers, expanding formulary access, favorable reimbursement support, and growing physician experience with the first and only approved treatment for TA-TMA,” CEO Gregory A. Demopulos said. Omeros launched Yartemlea in the U.S. in January for TA-TMA, or a severe, often fatal complication of bone marrow transplantation.

Omeros also noted several upcoming catalysts, including a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026. The company continues to advance its broader pipeline, including OMS527 for cocaine use disorder, and T-CAT programs targeting multidrug-resistant pathogens.

How Did OMER Retail Traders React?

On Stocktwits, retail sentiment around OMER stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.

A Stocktwits user opined that the after-hours price action does not justify the company’s “great” earnings call.

Another user said that they see the stock climbing to $20 as the EMA decision nears and further to $100 in time.

OMER stock has more than tripled in value over the past 12 months. 

Read More: ENVX Tumbles After Hours On Smartphone Battery Qualification Timeline Concerns

For updates and corrections, email newsroom[at]stocktwits[dot]com.